1 How to Install, Configure, Administer and Troubleshoot Linux.
How to successfully administer Nebido Information for ...
Transcript of How to successfully administer Nebido Information for ...
How
to
succ
essf
ully
adm
inis
ter
Neb
ido ®
Info
rmat
ion
for
hea
lth
care
pro
fess
ion
als
This
leafl
et p
rovi
des
info
rmat
ion
on
cer
tain
asp
ects
of N
ebid
o® a
dmin
istr
atio
n in
ord
er t
o
wid
en y
our
know
ledg
e on
eve
nts
that
mig
ht o
ccu
r du
rin
g or
aft
er t
he
Neb
ido®
inje
ctio
n
Bay
er P
harm
a A
GM
ülle
rstr
aße
178
1335
3 B
erlin
Ger
man
y
ww
w.b
ayer
.com
Chec
k fo
r co
ntra
indi
cati
ons
and
spec
ial w
arn
ings
acc
ordi
ng
to t
he
Prod
uct
In
form
atio
n/H
ealt
hca
re P
rofe
ssio
nal
Info
rmat
ion
Befo
re a
dmin
iste
rin
g th
e in
ject
ion
, ch
eck
the
pati
ent
for
any
cont
rain
dica
tion
s: a
ndr
ogen
-dep
ende
nt
carc
inom
a of
th
e pr
osta
te o
r of
th
e m
ale
mam
mar
y gl
and;
pas
t or
pre
sent
live
r tu
mou
rs; h
yper
sen
siti
vity
to
th
e ac
tive
su
bsta
nce
or
to a
ny
of t
he
exci
pien
ts. N
ebid
o® is
not
indi
cate
d fo
r u
se in
wom
en.
Neb
ido®
– t
he
lon
g-ac
tin
g te
stos
tero
ne
Neb
ido®
– p
repa
rin
g th
e in
ject
ion
Neb
ido®
(tes
tost
eron
e u
nde
can
oate
, TU
) is
a lo
ng-
acti
ng
test
oste
ron
e pr
epar
atio
n fo
r th
e tr
eatm
ent
of m
ale
hyp
ogon
adis
m c
onfi
rmed
by
clin
ical
sym
ptom
s an
d bi
och
emic
al t
ests
. Th
e in
tram
usc
ula
r in
ject
ion
form
s a
depo
t fr
om w
hic
h T
U is
gra
dual
ly re
leas
ed. A
s a
resu
lt, t
esto
ster
one
leve
ls o
f th
e pa
tien
t w
ill n
orm
alis
e an
d re
mai
n w
ith
in t
he
nor
mal
ran
ge fo
r 10
–14
wee
ks.
Do
not
refr
iger
ate
Han
dlin
g of
th
e vi
al
Glo
ves
shou
ld b
e w
orn
wh
ile re
mov
ing
the
plas
tic
cap
on t
he
vial
.
Ster
ilize
th
e ru
bber
mem
bran
eU
se a
n a
lcoh
ol w
ipe
to s
teri
lize
the
rubb
er
mem
bran
e w
hic
h is
now
exp
osed
bef
ore
w
ith
draw
ing
the
med
icat
ion
.
0203
X
Use
a 5
ml s
yrin
gePr
epar
atio
n o
f pa
tien
t
Nee
dle
size
s•
To w
ith
draw
th
e so
luti
on fr
om t
he
vial
, use
an
18G
(1.3
mm
) nee
dle
• Se
lect
th
e ap
prop
riat
e n
eedl
e si
ze a
ccor
din
g to
th
e pa
tien
t’s fa
t an
d m
usc
le m
ass
of t
he
glu
teal
regi
on
• Ex
pert
s re
com
men
d th
e u
se o
f a 2
0G (0
.9m
m),
21G
1 (0.8
mm
) or
22G
(0.7
mm
) nee
dle
to e
nsu
re a
slo
w
intr
amu
scu
lar
inje
ctio
n a
nd
depo
siti
on o
f Neb
ido®
Lay
the
pati
ent
dow
n in
a c
omfo
rtab
le p
osit
ion
• Th
e de
ep, i
ntra
mu
scu
lar
inje
ctio
n s
hou
ld b
e ad
min
iste
red
wit
h t
he
pati
ent
lyin
g do
wn
• Th
e be
d sh
ould
be
com
plet
ely
flat
an
d th
e pa
tien
t’s h
ands
sh
ould
be
kept
un
der
thei
r h
ead
• Yo
u s
hou
ld a
lso
rem
ind
the
pati
ent
to re
mai
n s
till
duri
ng
the
inje
ctio
n
Rela
x5m
lsy
ringe
0405
The
inje
ctio
n p
roce
ss –
ste
p-by
-ste
p
• A
s w
ith
all
oily
sol
uti
ons,
Neb
ido®
mu
st b
e in
ject
ed s
tric
tly
intr
amu
scu
larl
y an
d ve
ry s
low
ly
• It
is re
com
men
ded
to in
ject
Neb
ido®
ove
r ap
prox
imat
ely
2 m
inu
tes
• A
fter
sel
ecti
ng
the
inje
ctio
n s
ite,
cle
anse
th
e ar
ea w
ith
an
ant
isep
tic
• If
th
ere
is li
ttle
mu
scle
mas
s, y
ou m
ay n
eed
to p
inch
up
2 to
3 e
dges
of t
he
glu
teal
mu
scle
to
prov
ide
mor
e vo
lum
e an
d ti
ssu
e to
inse
rt t
he
nee
dle
• In
sert
th
e n
eedl
e in
to t
he
skin
at
a 90
° an
gle
to e
nsu
re it
is d
eepl
y em
bedd
ed in
th
e m
usc
le
• G
rasp
th
e ba
rrel
of t
he
syri
nge
firm
ly w
ith
on
e h
and.
Usi
ng
the
oth
er h
and,
pu
ll th
e pl
un
ger
back
to
aspi
rate
for
bloo
d
–
If b
lood
app
ears
, do
not
pro
ceed
wit
h t
he
inje
ctio
n. T
ake
the
nee
dle
out
of t
he
pati
ent
imm
edia
tely
an
d re
plac
e it
–
Car
efu
lly re
peat
th
e st
eps
for
inje
ctio
n
• If
no
bloo
d is
asp
irat
ed, h
old
the
nee
dle
posi
tion
to
avoi
d an
y m
ovem
ent
• A
pply
th
e in
ject
ion
ver
y sl
owly
by
depr
essi
ng
the
plu
nge
r ca
refu
lly a
nd
at a
con
stan
t ra
te u
ntil
all
the
med
icat
ion
is d
eliv
ered
(ide
ally
ove
r 2
min
ute
s)
• If
pos
sibl
e, u
se y
our
free
han
d to
man
ual
ly p
robe
or
chec
k fo
r de
pot
form
atio
n
• W
ith
draw
th
e n
eedl
e
Perf
orm
ing
the
inje
ctio
n
The
pref
erre
d si
te fo
r in
tram
usc
ula
r in
ject
ion
is t
he
glu
teu
s m
ediu
s m
usc
le lo
cate
d in
th
e u
pper
ou
ter
quad
rant
of t
he
butt
ock.
Car
e m
ust
be
take
n t
o pr
even
t th
e n
eedl
e fr
om h
itti
ng
the
supe
rior
gl
ute
al a
rter
y an
d sc
iati
c n
erve
. Neb
ido®
sh
ould
not
be
split
into
por
tion
s an
d it
sh
ould
nev
er b
e ad
min
iste
red
into
th
e u
pper
arm
or
the
thig
h.
At a 90
°an
gle
GLUTEUS
MED
IUS
GLU
TEU
SM
AX
IMU
S
SUPE
RIO
RG
LUTE
AL
ART
ERY
INFE
RIO
RG
LUTE
AL
ART
ERY
PIRF
ORM
IS
0607
The
pati
ent
shou
ld b
e ob
serv
ed d
uri
ng
and
imm
edia
tely
aft
er e
ach
inje
ctio
n o
f N
ebid
o® in
ord
er
to a
llow
for
earl
y re
cogn
itio
n o
f po
ssib
le s
ign
s an
d sy
mpt
oms
wh
ich
may
indi
cate
pu
lmon
ary
oily
m
icro
embo
lism
(PO
ME)
.
Reco
mm
ende
d tr
eatm
ent
sch
edu
leRi
sk m
anag
emen
t of
Neb
ido®
-tre
ated
pat
ient
s
Pulm
onar
y oi
ly m
icro
embo
lism
POM
E is
an
inje
ctio
n-b
ased
reac
tion
an
d is
pa
thop
hysi
olog
ical
ly re
late
d to
fat
embo
lism
sy
ndr
ome.
It c
an o
ccu
r fol
low
ing
dire
ct v
ascu
lar o
r ly
mph
ovas
cula
r del
iver
y of
oil-
base
d pr
epar
atio
ns,
w
hic
h th
en re
ach
the
lun
g fr
om v
enou
s ci
rcu
lati
on
and
righ
t h
eart
ou
tpu
t.
Pulm
onar
y m
icro
embo
lism
of o
ily s
olu
tion
s ca
n in
ra
re c
ases
lead
to s
ign
s an
d sy
mpt
oms
such
as:
cou
gh
(or u
rge
to c
ough
), dy
spn
oea,
mal
aise
, hyp
erh
idro
sis,
ch
est
pain
, diz
zin
ess,
par
aest
hes
ia, o
r syn
cope
.
Thes
e re
acti
ons
may
occ
ur d
uri
ng
or im
med
iate
ly
afte
r th
e in
ject
ion
an
d ar
e re
vers
ible
. Tre
atm
ent
is
usu
ally
su
ppor
tive
, e.g
. by
adm
inis
trat
ion
of
supp
lem
enta
l oxy
gen
.
Som
etim
es th
ese
sym
ptom
s m
ay b
e di
fficu
lt to
di
stin
guis
h fr
om a
n a
llerg
ic re
acti
on w
hic
h c
an o
ccu
r w
ith
use
of a
ny in
ject
able
pro
duct
.
Susp
ecte
d an
aphy
lact
ic re
acti
ons
afte
r Neb
ido®
in
ject
ion
hav
e be
en re
port
ed.
Neb
ido®
– t
he
prep
arat
ion
Neb
ido®
is a
n o
ily s
olu
tion
th
at c
onta
ins
1000
mg
TU d
isso
lved
in 4
ml c
asto
r oi
l.
As
wit
h a
ll oi
ly s
olu
tion
s, N
ebid
o® m
ust
be
inje
cted
str
ictl
y in
tram
usc
ula
rly
and
very
slo
wly
.
Intr
amu
scu
lar
inje
ctio
n o
f an
oil-
base
d pr
epar
atio
n re
quir
es s
peci
al c
are
to p
reve
nt
acci
dent
al, d
irec
t de
liver
y of
th
e oi
l-ba
sed
solu
tion
to
the
vasc
ula
r sy
stem
.
Neb
ido®
is in
ject
ed in
inte
rval
s of
10–
14 w
eeks
.
Star
tin
g tr
eatm
ent
Seru
m t
esto
ster
one
leve
ls s
hou
ld b
e m
easu
red
befo
re s
tart
an
d du
rin
g in
itia
tion
of t
reat
men
t. D
epen
din
g on
se
rum
tes
tost
eron
e le
vels
an
d cl
inic
al s
ympt
oms,
th
e fi
rst
inje
ctio
n in
terv
al m
ay b
e re
duce
d to
a m
inim
um
of
6 w
eeks
as
com
pare
d to
th
e re
com
men
ded
ran
ge o
f 10
to 1
4 w
eeks
for
mai
nten
ance
. Wit
h t
his
load
ing
dose
, su
ffici
ent
stea
dy s
tate
tes
tost
eron
e le
vels
may
be
ach
ieve
d m
ore
rapi
dly.
Mai
nten
ance
an
d in
divi
dual
isat
ion
of
trea
tmen
tA
fter
th
is “
load
ing
dose
”, fu
rth
er in
ject
ion
s sh
ould
be
give
n w
ith
in t
he
reco
mm
ende
d ra
nge
of 1
0–14
wee
ks.
Car
efu
l mon
itor
ing
of s
eru
m t
esto
ster
one
leve
ls is
requ
ired
du
rin
g m
aint
enan
ce o
f tre
atm
ent.
It is
adv
isab
le
to m
easu
re t
esto
ster
one
seru
m le
vels
regu
larl
y.
Mea
sure
men
ts s
hou
ld b
e pe
rfor
med
at
the
end
of a
n in
ject
ion
inte
rval
an
d cl
inic
al s
ympt
oms
con
side
red
for
indi
vidu
alis
atio
n o
f th
erap
y w
ith
Neb
ido®
. Th
ese
seru
m le
vels
sh
ould
be
wit
hin
th
e lo
wer
th
ird
of t
he
nor
mal
ra
nge
. Ser
um
leve
ls b
elow
nor
mal
ran
ge w
ould
indi
cate
th
e n
eed
for
a sh
orte
r in
ject
ion
inte
rval
. In
cas
e of
h
igh
ser
um
leve
ls a
n e
xten
sion
of t
he
inje
ctio
n in
terv
al m
ay b
e co
nsi
dere
d.
06
1830
Wee
ks o
f tr
eatm
ent
Mea
sure
men
t of
ser
um
tes
tost
eron
efo
r in
divi
dual
isat
ion
of
ther
apy
Load
ing
dose
12 w
eeks
12 w
eeks
6 w
eeks
0809
1011
Safe
ty m
onit
orin
g du
rin
g te
stos
tero
ne
repl
acem
ent
ther
apy
Peri
odic
ch
eck-
ups
du
rin
g lo
ng-
term
an
drog
en t
her
apy
are
reco
mm
ende
d fo
r pr
osta
te d
isea
se, h
aem
oglo
bin
, h
aem
atoc
rit
and
liver
fun
ctio
n t
ests
.
Pros
tate
saf
ety
Prio
r to
init
iati
on o
f tes
tost
eron
e th
erap
y, a
ll pa
tien
ts m
ust
un
derg
o a
deta
iled
pros
tate
ex
amin
atio
n (d
igit
al re
ctal
exa
min
atio
n a
nd
dete
rmin
atio
n o
f ser
um
PSA
) in
ord
er t
o
excl
ude
ris
k of
pre
-exi
stin
g pr
osta
tic
can
cer.
Aft
er s
tart
ing
test
oste
ron
e th
erap
y, c
aref
ul
and
regu
lar
mon
itor
ing
for
pros
tate
dis
ease
sh
ould
be
perf
orm
ed in
acc
orda
nce
wit
h
reco
mm
ende
d st
anda
rd o
f car
e m
eth
ods
(dig
ital
rect
al e
xam
inat
ion
an
d se
rum
PSA
) at
3–6
mon
ths,
at
12 m
onth
s an
d at
leas
t an
nu
ally
th
erea
fter
(tw
ice
year
ly in
eld
erly
pa
tien
ts a
nd
pati
ents
at
risk
).2
Hae
mat
ocri
t an
d h
aem
oglo
bin
Poly
cyth
aem
ia o
ccas
ion
ally
dev
elop
s du
rin
g te
stos
tero
ne
trea
tmen
t. T
her
efor
e, h
aem
atol
ogic
al a
sses
smen
t is
indi
cate
d be
fore
tre
atm
ent,
aft
er 3
–4 m
onth
s an
d 12
mon
ths
in t
he
firs
t ye
ar a
nd
then
an
nu
ally
th
erea
fter
. D
ose
adju
stm
ents
may
be
nec
essa
ry in
cas
e of
ele
vate
d h
aem
atoc
rit
and/
or h
aem
oglo
bin
.2
Neb
ido®
(Tes
tost
eron
e u
nde
can
oate
) EU
Ess
enti
al In
form
atio
nN
ebid
o 10
00 m
g/4
ml,
solu
tion
for
in
ject
ion
. Re
fer
to S
mPC
(da
te o
f re
visi
on:
Nov
embe
r 20
12)
befo
re p
resc
ribi
ng.
Com
posi
tion
: 4
ml
solu
tion
con
tain
ing
1000
mg
test
oste
ron
e u
nde
can
oate
as
acti
ve i
ngr
edie
nt
and
ben
zyl
ben
zoat
e an
d ca
stor
oil
as e
xcip
ien
ts.
Indi
cati
ons:
Tes
tost
eron
e re
plac
emen
t th
erap
y of
co
nfi
rmed
m
ale
hyp
ogon
adis
m.
Con
trai
ndi
cati
ons:
A
ndr
ogen
-dep
ende
nt
carc
inom
a of
th
e pr
osta
te o
r of
th
e m
ale
mam
mar
y gl
and;
pas
t or
pre
sen
t liv
er
tum
ours
; h
yper
sen
siti
vity
to
the
acti
ve s
ubs
tan
ce o
r to
an
y of
th
e ex
cipi
ents
. Sp
ecia
l war
nin
gs a
nd
prec
auti
ons:
Neb
ido
is n
ot r
ecom
men
ded
for
use
in c
hild
ren
an
d ad
oles
cen
ts. N
ebid
o is
not
indi
cate
d fo
r u
se in
wom
en. P
rior
to
test
oste
ron
e in
itia
tion
, all
pati
ents
mu
st u
nde
rgo
a de
taile
d ex
amin
atio
n in
ord
er t
o ex
clu
de a
ri
sk o
f pre
-exi
stin
g pr
osta
tic
can
cer.
Car
efu
l an
d re
gula
r mon
itor
ing
of t
he
pros
tate
gl
and
and
brea
st m
ust
be
perf
orm
ed.
The
follo
win
g la
bora
tory
par
amet
ers
shou
ld b
e ch
ecke
d pe
riod
ical
ly:
test
oste
ron
e, h
aem
oglo
bin
, h
aem
atoc
rit,
an
d liv
er f
un
ctio
n t
ests
. A
ndr
ogen
s m
ay a
ccel
erat
e th
e pr
ogre
ssio
n o
f su
b-cl
inic
al
pros
tati
c ca
nce
r an
d be
nig
n p
rost
atic
hyp
erpl
asia
. N
ebid
o sh
ould
be
use
d w
ith
ca
uti
on i
n c
ance
r pa
tien
ts a
t ri
sk o
f h
yper
calc
aem
ia.
Regu
lar
mon
itor
ing
of
seru
m c
alci
um
con
cen
trat
ion
s is
rec
omm
ende
d in
th
ese
pati
ents
. Be
nig
n a
nd
mal
ign
ant
liver
tu
mou
rs h
ave
been
rep
orte
d in
pat
ien
ts r
ecei
vin
g te
stos
tero
ne
repl
acem
ent
ther
apy.
In
pat
ien
ts s
uff
erin
g fr
om s
ever
e ca
rdia
c, h
epat
ic o
r re
nal
in
suff
icie
ncy
or
isch
aem
ic h
eart
dis
ease
, tre
atm
ent
wit
h t
esto
ster
one
may
cau
se
seve
re c
ompl
icat
ion
s ch
arac
teri
sed
by o
edem
a w
ith
or
wit
hou
t co
nge
stiv
e ca
rdia
c fa
ilure
. In
su
ch c
ase,
tre
atm
ent
mu
st b
e st
oppe
d im
med
iate
ly. T
he
limit
atio
ns
of
usi
ng
intr
amu
scu
lar i
nje
ctio
ns
in p
atie
nts
wit
h a
cqu
ired
or i
nh
erit
ed b
lood
clo
ttin
g ir
regu
lari
ties
alw
ays
hav
e to
be
obse
rved
. Neb
ido
shou
ld b
e u
sed
wit
h c
auti
on in
pa
tien
ts w
ith
epi
leps
y an
d m
igra
ine,
as
the
con
diti
ons
may
be
aggr
avat
ed. A
thle
tes
shou
ld b
e ad
vise
d th
at N
ebid
o co
nta
ins
an a
ctiv
e su
bsta
nce
wh
ich
may
pro
duce
a
posi
tive
rea
ctio
n i
n a
nti
-dop
ing
test
s. A
ndr
ogen
s ar
e n
ot s
uit
able
for
en
han
cin
g m
usc
ula
r de
velo
pmen
t in
hea
lth
y in
divi
dual
s or
for
incr
easi
ng
phys
ical
abi
lity.
As
wit
h a
ll oi
ly s
olu
tion
s, N
ebid
o m
ust
be
inje
cted
str
ictl
y in
tram
usc
ula
rly
and
very
sl
owly
(ove
r tw
o m
inu
tes)
. Pu
lmon
ary
mic
roem
bolis
m o
f oi
ly s
olu
tion
s ca
n in
rar
e ca
ses
lead
to s
ign
s an
d sy
mpt
oms
such
as
cou
gh, d
yspn
oea,
mal
aise
, hyp
erh
idro
sis,
ch
est p
ain
, diz
zin
ess,
par
aest
hes
ia, o
r syn
cope
. Th
ese
reac
tion
s m
ay o
ccu
r du
rin
g or
im
med
iate
ly a
fter
th
e in
ject
ion
an
d ar
e re
vers
ible
. Tre
atm
ent
is u
sual
ly s
upp
orti
ve,
e.g.
by
ad
min
istr
atio
n
of
supp
lem
enta
l ox
ygen
. U
nde
sira
ble
effe
cts:
M
ost
freq
uen
t u
nde
sira
ble
effe
cts:
acn
e an
d in
ject
ion
sit
e pa
in. S
usp
ecte
d an
aph
ylac
tic
reac
tion
s af
ter
Neb
ido
inje
ctio
n h
ave
been
rep
orte
d. A
ndr
ogen
s m
ay a
ccel
erat
e th
e pr
ogre
ssio
n o
f su
b-cl
inic
al p
rost
atic
can
cer
and
ben
ign
pro
stat
ic h
yper
plas
ia.
Oth
er c
omm
on a
dver
se d
rug
reac
tion
s (A
DRs
): p
olyc
yth
aem
ia, w
eigh
t in
crea
sed,
h
ot f
lush
, pr
osta
te s
peci
fic
anti
gen
in
crea
sed,
pro
stat
e ex
amin
atio
n a
bnor
mal
, be
nig
n p
rost
ate
hyp
erpl
asia
, in
ject
ion
sit
e re
acti
ons
(inje
ctio
n d
isco
mfo
rt, p
ruri
tus,
eryt
hem
a, h
aem
atom
a, i
rrit
atio
n a
nd
reac
tion
). U
nco
mm
on A
DRs
: H
aem
atoc
rit
incr
ease
d, r
ed b
lood
cel
l cou
nt
incr
ease
d, h
aem
oglo
bin
incr
ease
d, h
yper
sen
siti
vity
, in
crea
sed
appe
tite
, gl
ycos
ylat
ed h
aem
oglo
bin
in
crea
sed,
hyp
erch
oles
tero
laem
ia,
bloo
d tr
igly
ceri
des
incr
ease
d, b
lood
ch
oles
tero
l in
crea
sed,
dep
ress
ion
, em
otio
nal
di
sord
er,
inso
mn
ia,
rest
less
nes
s,
aggr
essi
on,
irri
tabi
lity,
h
eada
che,
m
igra
ine,
tr
emor
, car
diov
ascu
lar d
isor
der,
hyp
erte
nsi
on, d
izzi
nes
s, b
ron
chit
is, s
inu
siti
s, c
ough
, dy
spn
oea,
sn
orin
g, d
ysph
onia
, di
arrh
oea,
nau
sea,
liv
er f
un
ctio
n t
est
abn
orm
al,
aspa
rtat
e am
inot
ran
sfer
ase
incr
ease
d, a
lope
cia,
ery
them
a, r
ash
, pr
uri
tus,
dry
sk
in,
arth
ralg
ia,
pain
in
ext
rem
ity,
mu
scle
dis
orde
rs,
mu
scu
losk
elet
al s
tiff
nes
s,
bloo
d cr
eati
ne
phos
phok
inas
e in
crea
sed,
uri
ne
flow
dec
reas
ed, u
rin
ary
rete
nti
on,
uri
nar
y tr
act
diso
rder
, n
octu
ria,
dy
suri
a,
pros
tati
c in
trae
pith
elia
l n
eopl
asia
, pr
osta
te in
dura
tion
, pro
stat
itis
, pro
stat
ic d
isor
der,
libid
o ch
ange
s, t
esti
cula
r pa
in,
brea
st in
dura
tion
, bre
ast
pain
, gyn
aeco
mas
tia,
oes
trad
iol i
ncr
ease
d, t
esto
ster
one
incr
ease
d, f
atig
ue,
ast
hen
ia,
hyp
erh
idro
sis.
Pu
lmon
ary
mic
roem
bolis
m o
f oi
ly
solu
tion
s ca
n in
rar
e ca
ses
lead
to
sign
s an
d sy
mpt
oms
such
as
cou
gh, d
yspn
oea,
m
alai
se,
hyp
erh
idro
sis,
ch
est
pain
, di
zzin
ess,
par
aest
hes
ia,
or s
ynco
pe.
Oth
er
know
n A
DRs
of
test
oste
ron
e-co
nta
inin
g pr
epar
atio
ns:
ner
vou
snes
s, h
osti
lity,
sl
eep
apn
oea,
var
iou
s sk
in r
eact
ion
s in
clu
din
g se
borr
hoe
a, in
crea
sed
freq
uen
cy o
f er
ecti
ons,
rar
e ca
ses
of p
ersi
sten
t, pa
infu
l ere
ctio
ns
(pri
apis
m),
in v
ery
rare
cas
es
jau
ndi
ce. T
her
apy
wit
h h
igh
dos
es o
f te
stos
tero
ne
com
mon
ly r
ever
sibl
y in
terr
upt
s or
red
uce
s sp
erm
atog
enes
is, t
her
eby
redu
cin
g th
e si
ze o
f th
e te
stic
les.
Hig
h-d
osed
or
lon
g-te
rm a
dmin
istr
atio
n o
f tes
tost
eron
e oc
casi
onal
ly in
crea
ses
the
occu
rren
ces
of w
ater
ret
enti
on a
nd
oede
ma.
Pos
olog
y an
d m
eth
od o
f ad
min
istr
atio
n:
Neb
ido
is i
nje
cted
eve
ry 1
0 to
14
wee
ks.
Neb
ido
is s
tric
tly
for
intr
amu
scu
lar
inje
ctio
n
and
mu
st b
e ad
min
iste
red
very
slo
wly
(ov
er t
wo
min
ute
s). C
are
shou
ld b
e ta
ken
to
in
ject
Neb
ido
deep
ly i
nto
th
e gl
ute
al m
usc
le f
ollo
win
g th
e u
sual
pre
cau
tion
s fo
r in
tram
usc
ula
r ad
min
istr
atio
n. S
peci
al c
are
mu
st b
e ta
ken
to
avoi
d in
trav
asal
in
ject
ion
. Th
e fi
rst
inje
ctio
n i
nte
rval
may
be
redu
ced
to a
min
imu
m o
f 6
wee
ks.
Neb
ido
is n
ot i
ndi
cate
d fo
r u
se i
n c
hild
ren
an
d ad
oles
cen
ts a
nd
it h
as n
ot b
een
ev
alu
ated
clin
ical
ly i
n m
ales
un
der
18 y
ears
of
age.
Leg
al C
ateg
ory:
Med
icin
al
prod
uct
su
bjec
t to
med
ical
pre
scri
ptio
n.
Mar
keti
ng
Au
thor
isat
ion
hol
der:
Bay
er
Phar
ma
AG
, 133
53 B
erlin
, Ger
man
y. F
or f
urt
her
det
ails
con
tact
you
r lo
cal
Baye
r Ph
arm
a or
gan
isat
ion
. Ver
sion
: 16
July
201
2.
Refe
renc
es1.
Sar
tori
us
G e
t al
. Asi
an J
And
rol 2
010;
12(2
):22
7–23
3.2.
Wan
g C
et
al. E
ur U
rol 2
009;
55:1
21–1
30.
Dat
e of
pre
para
tion
: Ju
ne
2013
G.G
M.M
H.0
3.20
13.0
198
Esse
ntia
l Pre
scri
bin
g In
form
atio
n
Any
sus
pect
ed a
dver
se d
rug
reac
tions
can
be
repo
rted
to:
Med
icin
es A
utho
rity,
Pos
t-lic
ensi
ng D
irect
orat
e, 2
03, L
evel
3, R
ue D
'Arg
ens,
Gira
GR
136
8, M
ALT
A,
or a
t: ht
tp://
ww
w.m
edic
ines
auth
ority
.gov
.mt/a
drpo
rtal
Tele
phon
e N
umbe
r: +3
56 2
343
9000
O
rA
lfred
Ger
a &
Son
s Lt
d, T
riq il
-Mas
ar, Q
orm
i QR
M 3
217,
MA
LTA
,or
at:
pv@
alfre
dger
a.co
m
Tel
epho
ne N
umbe
r: +3
56 2
1446
205